LOGIN  |  REGISTER
Surmodics

Stryker announces Annual Meeting of Shareholders

March 28, 2023 | Last Trade: US$328.45 1.82 0.56

Kalamazoo, Michigan, March 28, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced its 2023 Annual Meeting of Shareholders is scheduled as follows:

Wednesday, May 10, 2023 – 9:00 a.m. Eastern Time

The Meeting will be held virtually via the internet. Information about the webcast, which will include both the audio and the slide presentation from the meeting, is available on the Investor Relations page of our website at www.investorevents.stryker.com. To listen to the meeting as a guest dial (877) 328-2502 (U.S.) or (412) 317-5419 (International) and request the "Stryker Corporation Annual Meeting" when greeted by the operator.

A recording of the annual meeting will also be available from 10:00 a.m., Eastern Time, on Thursday, May 11, 2023 at www.virtualshareholdermeeting.com/SYK2023 until the definitive proxy statement for our 2024 Annual Meeting of Shareholders is filed with the United States Securities and Exchange Commission.

Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and hospital outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com.

Contacts

For investor inquiries please contact:
Jason Beach, Vice President, Investor Relations at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it. 

For media inquiries please contact:
Yin Becker, Vice President, Chief Corporate Affairs Officer at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it.


Chimerix

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB